Literature DB >> 27608599

STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation.

Ken Takashima1, Yohei Takeda1, Hiroyuki Oshiumi1, Hiroaki Shime1, Masaru Okabe2, Masahito Ikawa2, Misako Matsumoto1, Tsukasa Seya3.   

Abstract

An interferon-inducing DNA sensor STING participates in tumor rejection in mouse models. Here we examined what mechanisms contribute to STING-dependent growth retardation of B16 melanoma sublines by NK cells in vivo. The studies were designed using WT and STING KO black mice, and B16D8 (an NK-sensitive melanoma line having STING) and STING KO B16D8 sublines established for this study. The results from tumor-implant studies suggested that STING in host immune cells and tumor cells induced distinct profiles of chemokines including CXCL10, CCL5 and IL-33, and both participated in NK cell infiltration and activation in B16D8 tumor. Spontaneous activation of STING occurs in host-immune and tumor cells of this NK-sensitive tumor, thereby B16D8 tumor growth being suppressed in this model. Our data show that STING induces tumor cytotoxicity by NK cells through tumor and host immune cell network to contribute to innate surveillance and suppression of tumors in vivo.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antitumor immunity; B16 cell line; Interferon; NK cells; STING

Mesh:

Substances:

Year:  2016        PMID: 27608599     DOI: 10.1016/j.bbrc.2016.09.021

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

Review 1.  The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment.

Authors:  Samuel F Bakhoum; Lewis C Cantley
Journal:  Cell       Date:  2018-09-06       Impact factor: 41.582

Review 2.  Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways.

Authors:  Alessandra Zevini; David Olagnier; John Hiscott
Journal:  Trends Immunol       Date:  2017-01-07       Impact factor: 16.687

3.  A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity.

Authors:  Rebekah Watkins-Schulz; Pamela Tiet; Matthew D Gallovic; Robert D Junkins; Cole Batty; Eric M Bachelder; Kristy M Ainslie; Jenny P Y Ting
Journal:  Biomaterials       Date:  2019-03-14       Impact factor: 12.479

Review 4.  Post-Translational Modifications of STING: A Potential Therapeutic Target.

Authors:  Jiaqi Kang; Jie Wu; Qinjie Liu; Xiuwen Wu; Yun Zhao; Jianan Ren
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 5.  Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.

Authors:  Kyle M Garland; Taylor L Sheehy; John T Wilson
Journal:  Chem Rev       Date:  2022-02-02       Impact factor: 60.622

Review 6.  The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer.

Authors:  John Kwon; Samuel F Bakhoum
Journal:  Cancer Discov       Date:  2019-12-18       Impact factor: 38.272

7.  cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue.

Authors:  Hiromi Takaki; Ken Takashima; Hiroyuki Oshiumi; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa; Misako Matsumoto; Tsukasa Seya
Journal:  Med Sci (Basel)       Date:  2017-12-18

8.  Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel.

Authors:  Feihu Wang; Hao Su; Dongqing Xu; Wenbing Dai; Weijie Zhang; Zongyuan Wang; Caleb F Anderson; Mengzhen Zheng; Richard Oh; Fengyi Wan; Honggang Cui
Journal:  Nat Biomed Eng       Date:  2020-08-10       Impact factor: 25.671

Review 9.  Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.

Authors:  Vito Amodio; Gianluca Mauri; Nicole M Reilly; Andrea Sartore-Bianchi; Salvatore Siena; Alberto Bardelli; Giovanni Germano
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

10.  STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.

Authors:  Matteo Rossi; Susanna Carboni; Wilma Di Berardino-Besson; Erika Riva; Marie-Laure Santiago-Raber; Elodie Belnoue; Madiha Derouazi
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.